Ohio Willow Wood Co. v. Alps S., LLC

• Citation: 735 F.3d 1333
• Decision Date: 23 January 2014
• Docket Number: Nos. 2012–1642,2013–1024.,s. 2012–1642
• Parties: The OHIO WILLOW WOOD COMPANY, Plaintiff–Appellant, v. ALPS SOUTH, LLC, Defendant–Cross Appellant.
• Court: United States Courts of Appeals. United States Court of Appeals for the Federal Circuit

735 F.3d 1333

The OHIO WILLOW WOOD COMPANY, Plaintiff–Appellant,

v.ALPS SOUTH, LLC, Defendant–Cross Appellant.

Nos. 2012–1642, 2013–1024.

United States Court of Appeals,Federal Circuit.

Nov. 15, 2013.

Rehearing and Rehearing En Banc Denied Jan. 23, 2014.^*

Jeffrey S. Standley, Standley Law Group, LLP, of Dublin, OH, argued for plaintiff-appellant. With him on the brief were James L. Kwak, F. Michael Speed, Jr., and Michael Stonebrook.

Ronald A. Christaldi, Shumaker, Loop & Kendrick, LLP, of Tampa, FL, argued for defendant-cross appellant. With him on the brief was Mindi M. Richter. Of counsel on the brief was David W. Wicklund, of Toledo, OH.

Before DYK, BRYSON, and REYNA, Circuit Judges.

REYNA, Circuit Judge.

This suit was filed by The Ohio Willow Wood Company (“OWW”) against Alps South, LLC (“Alps”) for infringement of United States Patent No. 5,830,237 (the “'237 patent”). The United States District Court for the Southern District of Ohio granted summary judgment that: (1) OWW was collaterally estopped from challenging the invalidity of claims 1, 2, 4, 15, 16, and 20 of the '237 patent; (2) claims 18, 19, 21, 22, and 23 of the '237 patent were invalid for obviousness; and (3) Alps failed to raise a genuine issue of material fact with respect to inequitable conduct. We affirm on the issues of collateral estoppel and obviousness, but reverse and remand on the issue of inequitable conduct.

I. Background

OWW is the owner of a family of related patents directed to cushioning devices that go over the residual stumps of amputated limbs to make the use of prosthetics more comfortable. A variety of these patents have been asserted in patent infringement suits and many have also been involved in reexamination proceedings before the Patent and Trademark Office (“PTO”).

In the present suit, OWW filed its complaint against Alps for infringement of the '237 patent on December 27, 2004. The '237 patent, entitled “Gel and Cushioning Devices,” lists Bruce G. Kania as the sole inventor and has an application date of March 5, 1996. The parties exchanged contentions, documents, and testimonial evidence related to invalidity and infringement and on March 31, 2006, the district court issued its claim construction order. Shortly after receiving the claim construction order, Alps initiated the first of two consecutive ex parte reexaminations of the '237 patent in the PTO. The district court stayed the litigation during these reexamination proceedings.

A. The First Reexamination of the '237 patent

Alps requested the first ex parte reexamination of the '237 patent on October 5, 2006. The primary reference submitted by Alps to support this reexamination was a prior art gel liner manufactured by Silipos, Inc. (“Silipos”) called the “Silosheath.” The Silosheath is a sock-shaped piece of nylon fabric that was turned inside out and dipped into a mineral oil-based polymeric gel material to create a coating on the interior of the sheath. The gel coating acts as a cushion and the mineral oil lubricates the skin when worn over a residual limb.

The examiner reviewing Alps' reexamination request for the '237 patent was also responsible for a parallel reexamination proceeding involving OWW's U.S. Patent No. 6,964,688 (the “'688 patent”). The '688 patent is entitled “Tube Sock–Shaped Covering” and also lists Bruce G. Kania as the sole inventor. During reexamination of the '688 patent, the examiner issued a rejection of all challenged claims based on the Silosheath prior art. This same rejection applied equally against the similar claims of the '237 patent.

The examiner held an interview on July 16, 2007, to discuss the rejections. At the interview, OWW was represented by attorneys Mr. Eric M. Gayan and Mr. Jeff Standley, Mr. Jim Colvin, a representative of OWW, and Mr. Bruce Kania, the named inventor. To overcome the rejections, a sample Silosheath was shown to the examiner and OWW pointed out that the polymeric gel bled through the permeable nylon fabric, which resulted in small amounts of residual gel material on the exterior of the Silosheath. According to OWW, these small amounts of gel on the outer surface of the Silosheath created points of friction between a prosthetic and the Silosheath. The friction points would be uncomfortable to the user and cause the nylon fabric to rip or tear prematurely.

OWW argued that the '688 and '237 patents claimed gel liners that excluded any gel on the exterior surface of the fabric, thereby distinguishing them from the Silosheath. Based on this distinction, the examiner allowed OWW to overcome the Silosheath prior art by amending the claims to clarify that the gel coating was only on the interior of the claimed gel liners and, accordingly, excluded any liners with fabric that allowed gel to bleed through to the exterior surface. The PTO issued the first reexamination certificate for the amended '237 patent claims on September 2, 2008.

B. The Second Reexamination of the '237 patent

On September 8, 2008, six days after completion of the first reexamination, Alps initiated a second ex parte reexamination of the '237 patent challenging the validity of the amended claims based on another Silipos product called the “Single Socket Gel Liner” (“SSGL”). Alps argued that the SSGL was an invalidating prior art gel liner that did not have any gel on its exterior surface. Alps supported this assertion with a prior art advertisement of the SSGL and testimony from Mr. Jean–Paul Comtesse, who had been affiliated with Silipos and involved in the development and production of both the Silosheath and SSGL.

The prior art advertisement was published on January 1, 1995, in a prosthetics trade magazine called O & P Business News (the “1995 COMFORT ZONE” reference). The advertisement included a photograph of an actual device being worn and bearing a graphical label identifying it as a “Silipos, Gel Liner, Made in USA,” and the advertisement further indicated that the device in the photograph was the “Single Socket Gel Liner”:

IMAGE

The 1995 COMFORT ZONE reference further described the SSGL as a “[b]elow knee gel liner laminated with tri block copolymer.”

In addition to the advertisement, Alps provided the PTO with testimony from Mr. Comtesse in the form of a declaration and deposition transcript. The deposition occurred in the present litigation prior to the court's issuance of the stay. According to Alps, Mr. Comtesse's testimony proved that the SSGL did not have the same gel bleed-through issues as the Silosheath since he testified that the SSGL was constructed using a proprietary DuPont fabric called “Coolmax,” which was different from the nylon material used with the Silosheath. Mr. Comtesse testified that the Coolmax material was thicker and denser than nylon, making it impermeable so that gel did not bleed-through to the outer surface of the SSGL. Thus, Alps asserted that Mr. Comtesse's testimony, coupled with the disclosure of the SSGL advertisement, demonstrated that the amended claims from the first reexamination were invalid because the prior art SSGL had no gel on the exterior surface.

The examiner agreed with Alps and, ultimately, issued a final rejection that all claims of the '237 patent were obvious in view of the SSGL and other undisputed prior art. The examiner concluded that the 1995 COMFORT ZONE reference substantially disclosed the limitations of independent claim 1 of the '237 patent, but conceded that the advertisement was not conclusive regarding whether the SSGL had gel only on the interior of the liner. To address this shortcoming of the reference, the examiner accepted the Comtesse declaration and deposition testimony as proof that the SSGL was manufactured using the proprietary DuPont Coolmax material as a fabric. The examiner also accepted Comtesse's testimony that the Coolmax material was thicker and less permeable than the nylon fabric of the Silosheath and, accordingly, that the SSGL would not allow the gel to bleed-through to the exterior surface.

Faced with the examiner's final rejection of the claims in view of the SSGL, OWW appealed to the Board of Patent Appeals and Interferences (“BPAI”). OWW's arguments on appeal to the BPAI were entirely legal in nature. OWW asserted that the examiner's rejection was improper because it relied on the uncorroborated testimony of Mr. Comtesse, whom OWW characterized as a highly interested party. According to OWW, the uncorroborated testimony of a highly interested witness, such as Mr. Comtesse, was inadmissible and therefore could not be used to reject the claims. In its brief to the BPAI, OWW portrayed Mr. Comtesse as follows:

Mr. Comtesse admits that he is an interested party with respect to the outcome of this Reexamination and the related litigation. First, Mr. Comtesse is the owner and manager of Vorum Research Corporation ... a company that appears to sell products that compete with products offered by Patent Owner. Further, Mr. Comtesse has admitted that he continues to receive royalties on the Socket Gel Liner products he helped develop for Silipos. These Socket Gel Liner products would clearly compete with products of Patent Owner covered by the '237 patent. A party having a personal financial interest in the outcome of a patent suit is considered an interested party. It is well settled that issues of corroboration become more important and the amount of weight afforded to such testimony may be lessened when the witness is an interested party.

OWW also expressly denied the existence of any other evidence that would support Mr. Comtesse's testimony that SSGL was constructed using Coolmax fabric. According to OWW, the only evidence of record was the 1995 COMFORT ZONE advertisement, which was “wholly devoid of any mention of Coolmax.” OWW asserted that there was “no other evidence of any sort in this regard” and because “the Comtesse testimony is not corroborated as required it cannot be properly used to cure the very deficiencies in...